Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDWerewolf Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 2 | -$1.06 | -$0.20 | -$0.53 |
| Q2 2025 | 1 | -$0.56 | -$0.56 | -$0.56 |
| Q3 2025 | 1 | -$0.52 | -$0.52 | -$0.52 |
| Q4 2025 | 1 | -$0.49 | -$0.49 | -$0.49 |
| Q1 2026 | 1 | -$0.23 | -$0.23 | -$0.23 |
| Q2 2026 | 1 | -$0.25 | -$0.25 | -$0.25 |
| Q3 2026 | 1 | -$0.26 | -$0.26 | -$0.26 |
| Q4 2026 | 1 | -$0.29 | -$0.29 | -$0.29 |
| Q1 2027 | 1 | -$0.32 | -$0.32 | -$0.32 |
| Q2 2027 | 1 | -$0.32 | -$0.32 | -$0.32 |
| Q3 2027 | 1 | -$0.36 | -$0.36 | -$0.36 |
| Q4 2027 | 1 | -$0.42 | -$0.42 | -$0.42 |
Werewolf Therapeutics, Inc. Earnings Date And Information
Werewolf Therapeutics, Inc. last posted its earnings results on Thursday, November 7th, 2024. The company reported $-0.38 earnings per share for the quarter, topping analysts' consensus estimates of $-0.41 by $0.03. The company had revenue of 0 for the quarter and had revenue of 19.94 M for the year. Werewolf Therapeutics, Inc. has generated $-1 earnings per share over the last year ($-1.05 diluted earnings per share) and currently has a price-to-earnings ratio of -0.99. Werewolf Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 20th, 2025 based on prior year's report dates.
Werewolf Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/07/2024 | Q3 2024 | -$0.41 | -$0.38 | 0.03 | $709,317 | $0 |
| 08/08/2024 | Q2 2024 | -$0.38 | -$0.40 | -0.02 | $841,781 | $1.14 M |
| 05/03/2024 | Q1 2024 | -$0.35 | -$0.39 | -0.04 | $742,000 | |
| 03/07/2024 | Q4 2023 | -$0.43 | -$0.33 | 0.1 | $1.50 M | |
| 09/29/2023 | Q3 2023 | -$0.23 | $1.59 M | $5.90 M | ||
| 08/10/2023 | Q2 2023 | -$0.41 | -$0.14 | 0.27 | $3.15 M | $8.08 M |
| 05/11/2023 | Q1 2023 | -$0.49 | -$0.33 | 0.16 | $4.46 M | |
| 03/23/2023 | Q4 2022 | -$0.59 | -$0.35 | 0.24 | $7.28 M | |
| 11/10/2022 | Q3 2022 | -$0.60 | -$0.38 | 0.22 | $3.05 M | $4.97 M |
| 08/11/2022 | Q2 2022 | -$0.30 | -$0.52 | -0.22 | $5.00 M | $4.15 M |
| 05/10/2022 | Q1 2022 | -$0.60 | -$0.56 | 0.04 | $0 | |
| 03/24/2022 | Q4 2021 | -$0.56 | -$0.66 | -0.1 | $0 | |
| 11/10/2021 | Q3 2021 | -$0.45 | -$0.51 | -0.06 | $0 | |
| 08/12/2021 | Q2 2021 | -$0.28 | -$0.62 | -0.34 | $0 | |
| 06/10/2021 | Q1 2021 | -$0.46 | -$0.28 | 0.18 | $0 | |
| 12/30/2020 | Q4 2020 | -$0.83 | $0 | |||
| 09/29/2020 | Q3 2020 | -$0.68 | $0 | |||
| 06/29/2020 | Q2 2020 | $0.25 | $0 | |||
| 03/30/2020 | Q1 2020 | -$0.43 | $0 |
Werewolf Therapeutics, Inc. Earnings: FAQ's
When is Werewolf Therapeutics, Inc.'s earnings date?
Werewolf Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 20th, 2025 based off last year's report dates.
Did Werewolf Therapeutics, Inc. beat their earnings estimates last
quarter?
In the previous quarter, Werewolf Therapeutics, Inc. (:HOWL) reported $-0.38 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.41 by $0.03.
How can I listen to Werewolf Therapeutics, Inc.'s earnings conference
call?
The conference call for Werewolf Therapeutics, Inc.'s latest earnings report can be listened to online.
How can I read Werewolf Therapeutics, Inc.'s conference call transcript?
The conference call transcript for Werewolf Therapeutics, Inc.'s latest earnings report can be read online.
How much revenue does Werewolf Therapeutics, Inc. generate each year?
Werewolf Therapeutics, Inc. (:HOWL) has a recorded annual revenue of $19.94 M.
How much profit does Werewolf Therapeutics, Inc. generate each year?
Werewolf Therapeutics, Inc. (:HOWL) has a recorded net income of $19.94 M. Werewolf Therapeutics, Inc. has generated $-1.05 earnings per share over the last four quarters.
What is Werewolf Therapeutics, Inc.'s price-to-earnings ratio?
Werewolf Therapeutics, Inc. (:HOWL) has a price-to-earnings ratio of -0.99 and price/earnings-to-growth ratio is 0.09.